Exploring the Selinexor STOMP Trial image

Exploring the Selinexor STOMP Trial

Apr 05, 2022
07:00PM - 08:00PM EDT
Online Event
Overview

Join Dr. Chakraborty to learn about the Selinexor STOMP Trial and get answers to your questions like:

  1. Why test selinexor with so many different myeloma treatments aka why so many arms?
  2. What are we looking to discover and how soon could we get results?
  3. How can patients enroll in the trial, who qualifies for the clinical trials, and why should they join?
Agenda
07:00 PM
Introduction
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Rajshekhar Chakraborty.
07:05 PM
Presentation
Dr. Rajshekhar Chakraborty
Dr. Rajshekhar Chakraborty talks about Selinexor and the results we can see in clinical trials.
07:20 PM
Group Discussion
Audience
Type your questions in the chat and we will answer them!
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Dr. Rajshekhar Chakraborty

Dr. Rajshekhar Chakraborty

Rajshekhar Chakraborty, MD is an assistant professor of medicine at Columbia University Irving Medical Center in the division of hematology/oncology. After receiving his medical degree from University of Delhi, India, he completed his residency in internal medicine at Icahn School of Medicine at Mount Sinai-Queens Hospital Center. Subsequently, he spent three years as a clinical researcher in plasma cell disorders at the Mayo Clinic, Rochester, followed by fellowship in hematology/oncology at the Cleveland Clinic. Dr. Chakraborty cares primarily for patients with plasma cells disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom's macroglobulinemia. His research interests include clinical trials and outcomes research in plasma cell disorders.